GT Biopharma, Inc. (NASDAQ:GTBP – Get Free Report) shares fell 1.7% during trading on Thursday . The company traded as low as $2.34 and last traded at $2.34. 2,091 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 580,263 shares. The stock had previously closed at $2.38.
GT Biopharma Stock Performance
The company has a fifty day moving average of $2.34 and a two-hundred day moving average of $2.54. The company has a market cap of $5.93 million, a price-to-earnings ratio of -0.33 and a beta of 1.48.
GT Biopharma Company Profile
GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.
Further Reading
- Five stocks we like better than GT Biopharma
- Most Volatile Stocks, What Investors Need to Know
- IBM’s AI Offensive: Assessing IBM’s Path to Renewed Growth
- Investing in Travel Stocks Benefits
- Rockwell Automation: Tailwinds From Onshoring U.S. Production
- Growth Stocks: What They Are, Examples and How to Invest
- Is Energy Transfer Undervalued or a Value Trap?
Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
